Related Experiment Video
Updated: Jul 15, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data
1Department of Obstetrics and Gynecology and CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia, USA. archerdf@evms.edu
The Journal of Reproductive Medicine
|May 5, 2007
Summary
This study shows that a new hormone therapy combining drospirenone and 17beta-estradiol effectively treats menopausal symptoms. This combination also offers benefits for blood pressure and weight management.
Area of Science:
- Endocrinology
- Gynecology
- Pharmacology
Background:
- Menopausal hormone therapy (HT) is used to manage symptoms.
- Estrogen-based therapies carry risks.
- Novel progestogens are being investigated for safer HT options.
Purpose of the Study:
- To evaluate a novel hormone therapy (HT) combining drospirenone and 17beta-estradiol.
- To assess the efficacy and safety of this HT for menopausal symptom relief.
- To investigate additional benefits of this combination therapy.
Main Methods:
- Clinical study of a novel progestogen, drospirenone.
- Combination therapy with 17beta-estradiol.
- Evaluation of menopausal symptom relief, blood pressure, and weight changes.
Main Results:
- The drospirenone and 17beta-estradiol combination provided effective relief of menopausal symptoms.
- The therapy was found to be safe for managing menopausal symptoms.
- Beneficial effects on blood pressure and weight gain were observed.
Conclusions:
- The novel HT combination of drospirenone and 17beta-estradiol is effective and safe.
- This therapy offers additional cardiovascular and metabolic benefits.
- This combination represents a promising option for menopausal symptom management.
Related Concept Videos
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:22Birth Control Methods
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...